What Patient Advocacy Means in 2018

Sean Virani, MD, MSc, MPH, FRCPC, FCCS
President, Canadian Heart Failure Society, Etc.

Jillianne Code, MEd., PhD
President & Co-Founder, HeartLife Foundation
Disclosure Statements

S. Virani

Consulting Fees/Honoraria
AstraZeneca, Bayer, Boehringer Ingelheim, Novartis, Novo Nordisk, Medtronic, Otsuka, Pfizer, Servier, Takeda

Clinical Trials
Bayer, Medtronic, Novartis, Otsuka, Pfizer, Servier

J. Code

Honoraria
Servier
Audience Polling and Q&A

- Connecting to the Internet (this room only):
  - WiFi:
  - Password:

- Please use your mobile device, tablet, or PC and go to Slido.com
- Type in #HFAdvocacy18
What is the most important area in HF to focus on?

- Slido - What is the most important area in HF to focus on?
Objectives

After this workshop, participants will be able to:

- Identify how to build, nurture and leverage patient networks
- Interpret what patients want clinicians to do on their behalf
- Recognize key methods to empower the patient voice
What does advocacy mean in 2018?

- Slido – What does advocacy mean in 2018?
IHI Triple Aim

Dimension of Quality

Safe
Effective
Timely
Efficient
Equitable
Patient Centered
What are Quality Indicators?

“An instrument that is used to assess a measurable aspect of patient care as a guide to assessing performance of the healthcare organization or individual practitioners within the organization”

Multiple organizations, health systems, registries and guideline programs have developed KPIs [key performance indicators] but direct measures of patient centeredness and the patient experience of care are missing\textsuperscript{1}

\textsuperscript{1}Ezekowitz et al, Can J Cardiol 2017
## CCS HF Quality Indicators

### Process Measure

1. Daily assessment of blood chemistry
2. Chest x-ray
3. In-hospital use of ACE/ARB
4. Assessment of left ventricular function
5. Patient education at discharge
6. Documentation of 30-day readmission rate

---

1McKelvie RS et al, Can J Cardiol 2016 32(8):1038
P2P Spectrum of Advocacy for Heart Failure

LOCAL > PROVIDER > PROVINCIAL / TERRITORIAL > NATIONAL

peer to peer | P2P

patient to provider | P2P

patient to province | P2P

patient to policy | P2P
P2P LOCAL

- Slido – What are some local advocacy activities that you know of or have been engaged in?
P2P PROVIDER

- Slido – What are some provider-level advocacy activities that you know of or have been engaged in?
Slido – What are some provincial-level advocacy activities that you know of or have been engaged in?
P2P POLICY (National)

- Slido – What are some national-level advocacy activities that you know of or have been engaged in?
Editorial

The Need for Heart Failure Advocacy in Canada

Sean A. Virani, MD, MSc, MPH, FRCPC, FCCS, a Marc Bains, BBA, b Jillianne Code, MEd, PhD, b Anique Ducharme, MD, MSc, FRCPC, c Karen Harkness, RN, PhD, CCN(C), CHFN, d Jonathan G. Howlett, MD, FRCPC, FCCS, FACC, e Heather Ross, MD, MHSc, FRCPC, FCCS, FACC, f Bruce Sussex, MBBS, MSc, FRCPC, g and Shelley Zieroth, MD, FRCPC, FCCS; h on behalf of the Board and Membership of the Canadian Heart Failure Society

a Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada
b HeartLife Foundation, Vancouver, British Columbia, Canada
c Department of Medicine, Montreal Heart Institute, Montreal, Quebec, Canada
d CorHealth Ontario, Toronto, Ontario, Canada
The Need for HF Advocacy in Canada

- Impact of HF on Patients and Health System Outcomes
- Building a System of Care for Patients with HF
  - Quality improvement with quality data: The case for a national HF registry
  - Improved treatment outcomes require access to treatment
  - The patient voice in HF treatment, research, and advocacy
  - Driving change through collaboration: A call to action
Networks of Centres of Excellence in HF

TRANSFORM-HF

- The TRANSFORM Heart Failure (TRANSFORM HF) brings together health care professionals, academia, government, industry, not-for-profit, and patients to support new ideas and ground-breaking research. Ultimately, TRANSFORM HF will provide innovative therapies and solutions to reduce deaths and suffering caused by Heart Failure.
  - WP 1 - Discovery to Translation
  - WP 2 - Population-based Research and Innovation for System wide Management of Heart Failure (PRISM HF)
  - WP 3 - Health Policy: Developing Health Equity and Access to Quality HF Care in Canada
  - WP 4 - Digital Health Platform
What does advocacy mean in 2018?

- Slido - What does advocacy mean in 2018?
Thank you!

**Sean Virani**, MD, MSc, MPH, FRCPC, FCCS  
President, Canadian Heart Failure Society, Etc. Etc.

**Jillianne Code**, MEd., PhD  
President & Co-Founder, HeartLife Foundation